Skip to main content
Erschienen in: Virology Journal 1/2020

Open Access 01.12.2020 | Case Report

Chronic active Epstein–Barr virus infection manifesting as coronary artery aneurysm and uveitis

verfasst von: Haijuan Xiao, Bing Hu, Rongmu Luo, Huili Hu, Junmei Zhang, Weiying Kuang, Rui Zhang, Li Li, Gang Liu

Erschienen in: Virology Journal | Ausgabe 1/2020

Abstract

Background

Chronic active Epstein–Barr virus (CAEBV) infection is a type of lymphoproliferative disorder characterized by chronic or recurrent infectious mononucleosis (IM)-like symptoms, which can have less-frequent clinical presentations. The prognosis of CAEBV is poor, and hematopoietic stem cell transplantation (HSCT) has been shown to be the only potentially effective treatment. In this article, we present a special CAEBV case of a patient who had no typical IM-like symptoms at the early stage, but manifested with severe and progressive coronary artery aneurysm (CAA), abdominal aortic lesions, and severe uveitis. These manifestations were uncommon features and could only be blocked by HSCT.

Case presentation

A 4-year-old girl with no special medical history complained of decreased vision for 10 months and cough after physical activities for three months. The blurred vision grew rapidly worse within one month, until only light perception remained. She was diagnosed with uveitis and cataract, and received prednisone and ciclosporin A treatment. However, her vision did not improve. Physical examination showed slight hepatosplenomegaly. Ultrasonic cardiogram showed bilateral CAA (5.0 mm and 5.7 mm for inner diameters), and abdominal CT scan revealed a thickened aortic wall, as well as stenosis and dilation of the segmental abdominal aorta. Other significant findings were increased EBV-DNA (3.29 × 104 copies/mL) from peripheral blood, positive EBV antibodies (EBV-CA-IgG, EBV-EA-IgA, and EBV-NA-IgG), and positive EBV-encoded small RNAs found by bone marrow biopsy. Based on her clinical manifestations and evidence for EBV infection, we diagnosed CAEBV. She received allogeneic HSCT, and the cataract operation was performed after HSCT. EBV-DNA could not be detected in peripheral blood after HSCT. Her CAAs did not progress, and uveitis was well controlled. Her vision recovered gradually over the 3 years after HSCT.

Conclusions

We present a rare CAEBV case of a patient who suffered from uncommon and severe cardiovascular and ocular involvement that was relieved by HSCT. Therefore, early recognition and diagnosis of CAEBV are of vital importance to improve its prognosis. In summary, this atypical CAEBV case could help us recognize similar cases more easily, make the right diagnosis as early as possible, and deliver proper and timely treatment.
Hinweise
Haijuan Xiao and Bing Hu contributed equally to this work

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
allo-HSCT
Allogeneic HSCT
CAA
Coronary artery aneurysm
CAE
Coronary artery ectasia
CAEBV
Chronic active Epstein–Barr virus infection
CMV
Cytomegalovirus
EBERs
EBV-encoded small RNAs
ECM
Extracellular matrix
HHV-8
Human herpes virus 8
HIV
Human immunodeficiency virus
HLH
Hemophagocytic lymphohistiocytosis
HSCT
Hematopoietic stem cell transplantation
HSV
Herpes simplex virus
IM
Infectious mononucleosis
LPDs
Lymphoproliferative disorders
NO
Nitric oxide
PAH
Pulmonary arterial hypertension
PIDs
Primary immunodeficiency diseases
MMPs
Matrix metalloproteinases
VEGF
Vascular endothelial growth factor
VZV
Varicella zoster virus
WES
Whole-exome sequencing

Background

Epstein–Barr virus (EBV) is a ubiquitous virus infecting more than 90% of the population worldwide. EBV infection in humans is usually asymptomatic and persists as a lifelong latent infection [1]. However, the infection or reactivation of EBV could result in various lymphoproliferative disorders (LPDs), including infectious mononucleosis (IM) and hematologic malignancies [2]. Chronic active EBV infection (CAEBV) is a severe disease with high morbidity and mortality, which exhibits a predisposition in East Asian populations. As a type of LPD, the clonal expansion of EBV-infected T or NK cells plays a central role in the disease’s pathogenesis. However, the detailed pathogenesis of CAEBV and the mechanism by which EBV induces proliferation of T and NK cells are not known [1]. CAEBV is characterized by chronic or recurrent IM-like symptoms, such as fever, hepatosplenomegaly, lymphadenopathy, and liver dysfunction. However, CAEBV can also have other less frequent clinical presentations, or even fetal complications, such as central nervous system involvement, coronary artery aneurysm (CAA), interstitial pneumonia, digestive tract disorders, uveitis, and hemophagocytic lymphohistiocytosis (HLH) [3]. The prognosis of CAEBV is poor, and a series of therapies has been attempted, including anti-viral agents and immunosuppressors. However, hematopoietic stem cell transplantation (HSCT) has been shown to be the only potentially effective treatment [1].
Clonal proliferation of EBV-infected T or NK cells implies that CAEBV has a malignant nature. However, CAEBV is a chronic disease, and patients may remain in a stable condition for years without effective treatment [4]. Overt malignant lymphoma often occurs after a long course of disease. Some researchers propose that CAEBV is a continuous spectrum ranging from a smoldering phase to overt lymphoma [4]. It is commonly believed that hosts with normal immune functions possess the ability to recognize EBV-infected T and NK cells, and CAEBV patients are thus thought to have some defects in immunological function that cause inefficient recognition and/or killing of EBV-infected cells [1]. However, CAEBV patients have not been found to have obvious immunodeficiency until the present day [5]. Nevertheless, it should be noted that some immunocompromised patients have accompanying EBV infections, and their clinical manifestations are analogous to CAEBV [6]. The mutations of several genes, including SH2D1A, XIAP, CD27, CD70, MAGT1, and PRKCD, are shown to cause hosts to be susceptible to chronic or even fetal EBV infections [7]. Therefore, genetic testing is necessary to distinguish CAEBV from these primary immunodeficiency diseases (PIDs).
Coronary artery ectasia (CAE) is an uncommon cardiovascular disorder that is defined as localized or diffuse dilatation of the coronary lumen. CAA describes local dilatation in the coronary lumen that is 1.5-fold greater than in normal adjacent segments [8]. CAA could be seen in various disorders, including atherosclerosis, systemic inflammatory vasculitis (e.g., Kawasaki disease, Behcet’s disease), hereditary collagen defects (e.g., Marfan syndrome), infectious diseases (e.g., bacteria, mycobacteria), and congenital malformations [9]. Uveitis describes inflammation of the uvea, which contains the iris, ciliary body, and choroid. As intraocular inflammation can affect surrounding tissues, clinical uveitis may comprise inflammation of the retina, optic disc, and vitreous [10]. Uveitis may be the result of infectious (e.g., human herpes virus, tuberculosis, syphilis), non-infectious (mostly autoimmune or autoinflammatory), or masquerade (e.g., lymphoma) causes [11]. In this article, we will introduce a special CAEBV case of a patient who had no typical IM-like symptoms at the early stage, but whose illness manifested as uveitis, cataract, and cardiovascular involvement (CAA).

Case presentation

In July 2016, a 4-year-old girl was admitted to our department complaining of decreased vision and cough after physical activities. Ten months before hospitalization, she suffered from blurred vision, which grew rapidly worse within one month, until only light perception remained. In her local hospital, she was diagnosed with uveitis and cataract, and received prednisone, ciclosporin A, and local symptomatic treatment. The ocular lesions did not further exacerbate. Three months before hospitalization, the girl began to cough after exercise, with no fevers or other symptoms. Examinations showed normal blood routines and biochemical indicators, as well as a slightly increased erythrocyte sedimentation rate (ESR, 29 mm/h). There were no positive findings from the pulmonary CT scan or electrocardiogram, while an ultrasonic cardiogram showed bilateral CAAs, hypertrophic interventricular septum and left ventricular wall, and mitral and aortic valve insufficiency. Other significant findings were increased EBV-DNA (3.29 × 104 copies/mL) in the peripheral blood, and positive EBV antibodies (EBV-CA-IgG, EBV-EA-IgA, and EBV-NA-IgG). She was given aspirin and ganciclovir, and the cough subsided. This patient did not suffer from recurrent infections, having no other medical history and no family history of PID. She had an elder sister (17 years old), who was healthy with no known diseases. Physical examination showed vision loss (only light perception remaining), systolic murmur at the apex, and slight hepatosplenomegaly.
The examinations after hospitalization showed generally normal brain MRI manifestations, and similar results for ophthalmic tests and the ultrasonic cardiogram as before (inner diameters of left and right coronary arteries: 5.0 mm and 5.7 mm respectively). The pulmonary CT scan showed extensive parenchymal and interstitial lesions of the lungs bilaterally (Fig. 1a), and abdominal CT scan revealed a thickened aortic wall, as well as stenosis and dilation of the segmental abdominal aorta (Fig. 1b). There were no apparent abnormal findings in other vessels. Blood EBV-DNA and EBV antibodies were still positive, but autoantibodies were negative. There was no evidence for other infections, including other human herpes viruses [such as herpes simplex virus (HSV), varicella zoster virus (VZV), cytomegalovirus (CMV), and human herpes virus 8 (HHV-8)], human immunodeficiency virus (HIV), tuberculosis, toxoplasmosis, and syphilis. The immunoglobulin and complement levels were within normal range. Lymphocyte subgroups showed an increased percentage of CD3+ T cells and a decreased percentage of B cells and NK cells. The proportion of CD4+ T cells increased, and the ratio of CD4+ T to CD8+ T cells was also elevated (Table 1). A bone marrow smear was near normal, while bone marrow biopsy showed much infiltration of lymphoid cells, which had mildly irregular nuclei (Fig. 2a). Positive CD3/CD5/CD7/CD2 (partially)/TIA-1/GrB (sparsely)/ki67 (80%) and negative CD20/CD56 were revealed by immunohistochemistry, and the presence of EBV-encoded small RNAs (EBERs) was shown by in-situ hybridization (Fig. 2b). We did not find significant pathogenic genes by whole-exome sequencing (WES).
Table 1
Lymphocyte subsets before and 1 year after HSCT
 
Before HSCT
1 year after HSCT
Reference valuesa
CD3+ T lymphocytes (%)
91.4
85.7
55–82
CD3+CD4+ T lymphocytes (%)
74.5
36.0
27–57
CD3+CD8+ T lymphocytes (%)
15.4
41.0
14–33
CD4/CD8
4.8
0.9b
1.1–2
CD19+ B lymphocytes (%)
5.1
2.1
9–29
CD16+CD56+ NK cells (%)
1.5
10.2
7–40
aReference values used in Beijing Children’s Hospital
bThe value of another test at the same time was 1.25
Based on her clinical manifestations, increased EBV-DNA, positive EBV antibodies, and the pathological results of the bone marrow biopsy, we diagnosed the patient with CAEBV. She received allogeneic HSCT (allo-HSCT) in another hospital. The EBV-DNA in the peripheral blood could not be detected after HSCT. Compared with before HSCT, the percentage of CD4+ T cells and the ratio of CD4+ T to CD8+ T cells both decreased after HSCT (Table 1). The cataract operation was performed after HSCT. Her CAAs did not progress, and uveitis was well controlled. The patient’s vision recovered gradually over the 3 years after HSCT.

Discussion and conclusions

This is a rare CAEBV case of a patient who suffered from cardiovascular and ocular involvement. This patient showed severe and progressive CAAs and abdominal aortic lesions, which could only be blocked by HSCT. Uveitis was also controlled, and vision recovered gradually after HSCT. She did not have typical IM-like symptoms at the early stage, and slight hepatosplenomegaly did not occur until the very late stage. Therefore, early recognition and diagnosis of CAEBV are of vital importance to improve the prognosis of patients like the case described.
There have been several reports about CAEBV-associated cardiovascular diseases, including CAA, aortic aneurysms, myocarditis, pericardial effusion, and others, among which CAA and myocarditis are the major complications resulting in a poor prognosis [12, 13]. In Table 2, we summarize 20 CAEBV patients with coronary artery lesions reported in the literature, including 11 females and 9 males. There were 19 cases who had detailed descriptions about clinical features. The age at onset of CAEBV was between 2 years old and 16 years old, and 16 patients had symptoms at less than 10 years old. Eighteen patients had IM-like symptoms during the disease course. CAE, or even CAA, was found nearly simultaneously with CAEBV diagnosis in 12 cases, while these were found about 2–9 years after diagnosis in seven patients. Coronary lesions were described in detail in 13 patients: there were eight cases with bilateral CAE, four cases with left CAE, and one with right CAE only. The most severe coronary diameter was 8.2 mm. Only seven cases suffered from concomitant vascular lesions in the major branches of aorta. Three patients with pericardial effusion and two patients with pulmonary arterial hypertension (PAH) were noted, but no myocarditis was reported. Other organ lesions included pneumonia, nephritis, gastrointestinal diseases, and skin lesions. EBV-infected cell types were revealed in 12 cases: including 10 patients with infected T cells, one with infected NK cells, and one with infected γδT cells. Seventeen patients showed evidence for EBV infections, and all of them had positive EBV-DNA or EBERs. However, it should be noted that EBV antibodies were negative in one patient. As for the therapy, HSCT were not performed in 12 cases, among which eight patients died for various reasons. Six patients experienced HSCT: two patients were alive, and three patients died.
Table 2
Clinical manifestations and prognosis of previously reported CAEBV patients with coronary artery lesions
Pt
Sex
Onset age (years)
IM-like symptoms
Coronary artery lesions
Other cardiovascular complications
Other organ manifestations
Occurrence age (years)
Affected branch
Coronary diameter
Large-vessel arteritis
Myocarditis
Others
1
M
4
L, H
4
NA
NA
No
No
No
Interstitial pneumonitis, Sjögren syndrome
2
F
5
L, H
5
NA
NA
Abdominal aortic aneurysm
No
No
Interstitial pneumonitis
3
M
2
F, L, H
2
NA
NA
Dilation of the sinus of Valsalva
No
No
Interstitial pneumonitis
4
F
6
F, L, H
6
NA
NA
No
No
Pericarditis
Interstitial nephritis
5
F
5
F, H
5
NA
NA
Dilation of the sinus of Valsalva
No
Pericarditis
No
6
F
2
F, H
4
LCA
4 mm
No
No
No
Gastrointestinal tract, hypersensitivity to mosquito bites, hydroa vacciniforme
7
M
5
F, H
8
LCA
5 mm
No
No
No
No
8
M
6
F, H
10
LCA
4.5 mm
No
No
No
No
9
F
9
F, H
18
LCA, RCA
4 mm in RCA, 4 mm in LCA
No
No
No
No
10
M
11
H
14
LCA, RCA
NA
No
No
PAH, junctional ectopic tachycardia
No
11
F
10
F, H
10
LCA, RCA
NA
Dilation of bilateral common carotid and subclavian arteries, abdominal aorta and major branches, and bilateral common iliac arteries
No
No
No
12
M
2
F, H, L
2
LCA, RCA
6 mm in RCA, 3 mm in LCA
No
No
No
No
13
F
7
F, H, L
7
NA
NA
No
No
Pericardial effusion
No
14
M
2
F, H, L
2
LAD, LCX
6 mm in LMCA
No
No
No
No
15
F
5
F, H
5
LCA, RCA
8 mm in RCA, 5 mm in LCA
38 mm in the sinus of Valsalva, thoracic and abdominal aortic aneurysms
No
No
No
16
M
6
F, H
8
NA
NA
No
No
No
No
17
F
NA
NA
NA
LCA, RCA
NA
No
No
No
No
18
F
16
F, H, L
16
RCA (multiple stenoses and dilation)
NA
Aneurysms involving the aorta and its major branches, and bilateral common iliac arteries
No
No
No
19
F
6
F, H, L
6
LMCA, RCA
5 mm in LMCA, 8.2 mm in RCA
No
No
No
No
20
M
5
NA
9
LAD, RCA
NA
Dilatation of aortic sinus, minor dilatation of abdominal aortic stem and the distal section of superior mesenteric artery
No
PAH, cardiac insufficiency
Skin ulcers
Pt
Sex
Onset age (years)
IM-like symptoms
EBV status
Therapies—HSCT
Prognosis
Reports
Cell type
EBV copies (in PB)/EBERs
Abnormal EBV antibodies
1
M
4
L, H
T
EBERs (+)
Yes
No
Died (streptococcus pneumoniae) within 36 months from onset
Nakagawa et al. [25]
2
F
5
L, H
T
EBERs (+)
Yes
No
Died (respiratory failure) within 13 months from onset
Nakagawa et al. [25]
3
M
2
F, L, H
NA
EBV-DNA in cardiac tissues
Yes
No
Died within 5 years from onset
Kikuta et al. [26]
4
F
6
F, L, H
NA
EBV-DNA in cardiac and aortic tissues
Yes
No
Died within 5 years from onset
Kikuta et al. [26]
5
F
5
F, H
NA
EBV-DNA in cardiac tissues
Yes
No
Died within 5 years from onset
Kikuta et al. [26]
6
F
2
F, H
NK
3 × 103 copies/mL
No
Yes
Alive and disease free
Muneuchi et al. [12]
7
M
5
F, H
T
3 × 103 copies/mL
Yes
Yes
Died at 14 years
Muneuchi et al. [12]
8
M
6
F, H
T
5 × 104 copies/mL
Yes
Yes
Alive and disease free
Muneuchi et al. [12]
9
F
9
F, H
γδT
9 × 102 copies/mL
Yes
No
Died at 18 years
Muneuchi et al. [12]
10
M
11
H
NA
8.2 × 104 copies/μg DNA
Yes
Yes
Died (septic shock and multiple organ failure) within 13 days after transplantation
Fukuda et al. [27]
11
F
10
F, H
T
EBERs (+)
Yes
No
Died (respiratory failure due to diffuse alveolar damage)
Murakami et al. [28]
12
M
2
F, H, L
T
EBV-DNA in PBMC
Yes
NA
NA
Kikuta et al. [29]
13
F
7
F, H, L
T
EBV-DNA in pericardial effusion
Yes
Yes
Died (failure of umbilical cord blood transplantation)
Toubo et al. [30]
14
M
2
F, H, L
T
NA
Yes
No
NA
Kobayashi et al. [31]
15
F
5
F, H
T
EBERs (+)
Yes
No
Died (acute respiratory failure) within 13 months from onset
Nakagawa et al. [14]
16
M
6
F, H
T
NA
Yes
NA
NA
Ohga et al. [32]
17
F
NA
NA
NA
NA
NA
Yes
NA
Nishimura et al. [33]
18
F
16
F, H, L
NA
2.8 × 104 copies/mL
NA
No
NA
Jiang et al. [34]
19
F
6
F, H, L
NA
3.72 × 107 copies/mL
NA
No
NA
Xie et al. [35]
20
M
5
NA
NA
4.53 × 103 copies/mL in plasma, EBERs (+)
Yes
No
NA
Ba et al. [36]
NA not available, F fever, H hepatosplenomegaly, L lymphadenopathy, LAD left anterior descending artery, LCA left coronary artery, LCX left circumflex artery, LMCA left main coronary artery, RCA right coronary artery, PAH pulmonary arterial hypertension, PB peripheral blood, PBMC peripheral blood mononuclear cell
The potential mechanism of CAA in CAEBV patients has not yet been discovered. The pathological results showed lymphoid vasculitis, and two mechanisms were considered to play a central role in the onset and progression of cardiovascular lesions in CAEBV: EBV-infected T or NK lymphocyte infiltration and injuries in the myocardium and vessel walls, and EBV-induced high levels of pro- and anti-inflammatory cytokines resulting in inflammatory responses [12, 14, 15]. As for the pathogenesis of CAE or CAA, the activation of matrix-degrading enzymes (especially matrix metalloproteinases [MMPs]) and enzymatic degradation of the extracellular matrix (ECM) of the media are considered to be the most critical molecular events, which ultimately lead to excessive expansive arterial remodeling [9, 16]. This process is mediated via several factors, including increased levels of inflammatory mediators [e.g., vascular endothelial growth factor (VEGF), adhesion molecules], and induction of nitric oxide (NO) and its metabolite, which could trigger MMP formation [9, 16]. These factors have also been shown to play an important role in the pathogenesis of CAA in Kawasaki disease (the most common cause of CAA in childhood), but their functions in CAEBV still need to be further elucidated [1719]. It has been noted that CAA frequently occurs in association with more widespread vascular abnormalities, including aneurysms in the thoracic and abdominal aorta, as well as in the pulmonary and iliac arteries [20]. Our patient also suffered from segmental dilation of the abdominal aorta.
The reports of CAEBV-associated uveitis are rare, and the exact mechanisms are not fully understood. Infectious uveitis could arise from local infection, but is more commonly due to hematogenous spread of pathogens to the uvea [10]. The pathogenic antigens are presented to the leukocytes within the eye that are activated against infectious agents, and the release of chemokines could further attract leukocytes to the inflammation sites [21]. Therefore, uveitis occurs as collateral damage from immune responses and is the result of the breach of the blood-retinal barrier that occurs due to the inflammatory cascade [10, 21]. Wong et al. [22] described three CAEBV patients whose ocular involvement ranged from anterior uveitis to a severe panuveitis with cataract, vitritis, macular edema, and optic disc swelling. The onset age of three reported patients was between 15 years old and 30 years old, and they suffered from uveitis almost simultaneously with the CAEBV diagnosis or nearly 2 years after the diagnosis. Although their ocular lesions were relieved for a while by glucocorticoid and/or acyclovir therapies, the uveitis could relapse repeatedly [22]. Morishima et al. [36] reported a 7-year-old girl with CAEBV and associated uveitis who exhibited bilateral granulomatous iridocyclitis, mild vitritis, optic disk swelling, and left facial nerve palsy nearly 2 years after the diagnosis of CAEBV. Treatment with topical steroids, systemic interleukin-2, and splenectomy relieved the symptoms [23]. There have been no reports about the direct relationship between CAEBV and cataracts. However, cataract development is common among children with uveitis and is strongly related to the extent of inflammation recurrences [24]. Therefore, we believe the cataract of our patient may be secondary to her uveitis. She received a cataract operation after the HSCT, after which her vision recovered gradually.
In summary, this atypical CAEBV case with CAA and uveitis could help us recognize similar cases more easily, make the right diagnosis as early as possible, and deliver proper and timely treatment.

Acknowledgements

All the authors thank the patient and her parents for the support.
This study was approved by the Ethics Committee of Beijing Children’s Hospital, Capital Medical University, and performed according to the Declaration of Helsinki. Written informed consents were obtained from the parents of the recipient.
Written informed consents were obtained from the parents of the recipient for publication.

Competing interests

The authors declared that they had no competing interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Fujiwara S, Kimura H, Imadome K, Arai A, Kodama E, Morio T, Shimizu N, Wakiguchi H. Current research on chronic active Epstein–Barr virus infection in Japan. Pediatr Int. 2014;56(2):159–66.CrossRef Fujiwara S, Kimura H, Imadome K, Arai A, Kodama E, Morio T, Shimizu N, Wakiguchi H. Current research on chronic active Epstein–Barr virus infection in Japan. Pediatr Int. 2014;56(2):159–66.CrossRef
2.
Zurück zum Zitat Kim HJ, Ko YH, Kim JE, Lee SS, Lee H, Park G, Paik JH, Cha HJ, Choi YD, Han JH, et al. Epstein–Barr virus-associated lymphoproliferative disorders: review and update on 2016 WHO classification. J Pathol Transl Med. 2017;51(4):352–8.CrossRef Kim HJ, Ko YH, Kim JE, Lee SS, Lee H, Park G, Paik JH, Cha HJ, Choi YD, Han JH, et al. Epstein–Barr virus-associated lymphoproliferative disorders: review and update on 2016 WHO classification. J Pathol Transl Med. 2017;51(4):352–8.CrossRef
3.
Zurück zum Zitat Kimura H. Pathogenesis of chronic active Epstein–Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol. 2006;16(4):251–61.CrossRef Kimura H. Pathogenesis of chronic active Epstein–Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol. 2006;16(4):251–61.CrossRef
4.
Zurück zum Zitat Ohshima K, Kimura H, Yoshino T, Kim CW, Ko YH, Lee SS, Peh SC, Chan JK, Group CS. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int. 2008;58(4):209–17.CrossRef Ohshima K, Kimura H, Yoshino T, Kim CW, Ko YH, Lee SS, Peh SC, Chan JK, Group CS. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int. 2008;58(4):209–17.CrossRef
5.
Zurück zum Zitat Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, Okuno T, Murakami N, Yoshida K, Sawada A, et al. Defective Epstein–Barr virus in chronic active infection and haematological malignancy. Nat Microbiol. 2019;4(3):404–13.CrossRef Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, Okuno T, Murakami N, Yoshida K, Sawada A, et al. Defective Epstein–Barr virus in chronic active infection and haematological malignancy. Nat Microbiol. 2019;4(3):404–13.CrossRef
6.
Zurück zum Zitat Cohen JI. Primary immunodeficiencies associated with EBV disease. Curr Top Microbiol Immunol. 2015;390(Pt 1):241–65.PubMedPubMedCentral Cohen JI. Primary immunodeficiencies associated with EBV disease. Curr Top Microbiol Immunol. 2015;390(Pt 1):241–65.PubMedPubMedCentral
7.
Zurück zum Zitat Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, Franco JL, Holland SM, Klein C, Morio T, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24–64.CrossRef Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, Franco JL, Holland SM, Klein C, Morio T, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24–64.CrossRef
8.
Zurück zum Zitat Markis JE, Joffe CD, Cohn PF, Feen DJ, Herman MV, Gorlin R. Clinical significance of coronary arterial ectasia. Am J Cardiol. 1976;37(2):217–22.CrossRef Markis JE, Joffe CD, Cohn PF, Feen DJ, Herman MV, Gorlin R. Clinical significance of coronary arterial ectasia. Am J Cardiol. 1976;37(2):217–22.CrossRef
9.
Zurück zum Zitat Abou Sherif S, Ozden Tok O, Taskoylu O, Goktekin O, Kilic ID. Coronary artery aneurysms: a review of the epidemiology, pathophysiology, diagnosis, and treatment. Front Cardiovasc Med. 2017;4:24.CrossRef Abou Sherif S, Ozden Tok O, Taskoylu O, Goktekin O, Kilic ID. Coronary artery aneurysms: a review of the epidemiology, pathophysiology, diagnosis, and treatment. Front Cardiovasc Med. 2017;4:24.CrossRef
10.
Zurück zum Zitat Krishna U, Ajanaku D, Denniston AK, Gkika T. Uveitis: a sight-threatening disease which can impact all systems. Postgrad Med J. 2017;93(1106):766–73.CrossRef Krishna U, Ajanaku D, Denniston AK, Gkika T. Uveitis: a sight-threatening disease which can impact all systems. Postgrad Med J. 2017;93(1106):766–73.CrossRef
11.
Zurück zum Zitat Deschenes J, Murray PI, Rao NA, Nussenblatt RB, International Uveitis Study Group. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm. 2008;16(1):1–2.CrossRef Deschenes J, Murray PI, Rao NA, Nussenblatt RB, International Uveitis Study Group. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm. 2008;16(1):1–2.CrossRef
12.
Zurück zum Zitat Muneuchi J, Ohga S, Ishimura M, Ikeda K, Yamaguchi K, Nomura A, Takada H, Abe Y, Hara T. Cardiovascular complications associated with chronic active Epstein–Barr virus infection. Pediatr Cardiol. 2009;30(3):274–81.CrossRef Muneuchi J, Ohga S, Ishimura M, Ikeda K, Yamaguchi K, Nomura A, Takada H, Abe Y, Hara T. Cardiovascular complications associated with chronic active Epstein–Barr virus infection. Pediatr Cardiol. 2009;30(3):274–81.CrossRef
13.
Zurück zum Zitat Kimura H, Morishima T, Kanegane H, Ohga S, Hoshino Y, Maeda A, Imai S, Okano M, Morio T, Yokota S, et al. Prognostic factors for chronic active Epstein–Barr virus infection. J Infect Dis. 2003;187(4):527–33.CrossRef Kimura H, Morishima T, Kanegane H, Ohga S, Hoshino Y, Maeda A, Imai S, Okano M, Morio T, Yokota S, et al. Prognostic factors for chronic active Epstein–Barr virus infection. J Infect Dis. 2003;187(4):527–33.CrossRef
14.
Zurück zum Zitat Nakagawa A, Ito M, Iwaki T, Yatabe Y, Asai J, Hayashi K. Chronic active Epstein–Barr virus infection with giant coronary aneurysms. Am J Clin Pathol. 1996;105(6):733–6.CrossRef Nakagawa A, Ito M, Iwaki T, Yatabe Y, Asai J, Hayashi K. Chronic active Epstein–Barr virus infection with giant coronary aneurysms. Am J Clin Pathol. 1996;105(6):733–6.CrossRef
15.
Zurück zum Zitat Fujiwara M, Shimozono H, Ono H, Fujita N, Nishimura S, Ueda K, Kaneko M. Polyclonal proliferation of lymphocytes containing the Epstein–Barr virus genome in a patient dying of myocarditis in chronic active Epstein–Barr virus infection. J Pediatr Hematol Oncol. 2003;25(1):85–8.CrossRef Fujiwara M, Shimozono H, Ono H, Fujita N, Nishimura S, Ueda K, Kaneko M. Polyclonal proliferation of lymphocytes containing the Epstein–Barr virus genome in a patient dying of myocarditis in chronic active Epstein–Barr virus infection. J Pediatr Hematol Oncol. 2003;25(1):85–8.CrossRef
16.
Zurück zum Zitat Antoniadis AP, Chatzizisis YS, Giannoglou GD. Pathogenetic mechanisms of coronary ectasia. Int J Cardiol. 2008;130(3):335–43.CrossRef Antoniadis AP, Chatzizisis YS, Giannoglou GD. Pathogenetic mechanisms of coronary ectasia. Int J Cardiol. 2008;130(3):335–43.CrossRef
17.
Zurück zum Zitat Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, Sasaki N, Asano H, Kyo S, Yokote Y. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation. 2001;104(8):860–3.CrossRef Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, Sasaki N, Asano H, Kyo S, Yokote Y. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation. 2001;104(8):860–3.CrossRef
18.
Zurück zum Zitat Ohno T, Igarashi H, Inoue K, Akazawa K, Joho K, Hara T. Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr. 2000;159(6):424–9.CrossRef Ohno T, Igarashi H, Inoue K, Akazawa K, Joho K, Hara T. Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr. 2000;159(6):424–9.CrossRef
19.
Zurück zum Zitat Adewuya O, Irie Y, Bian K, Onigu-Otite E, Murad F. Mechanism of vasculitis and aneurysms in Kawasaki disease: role of nitric oxide. Nitric Oxide. 2003;8(1):15–25.CrossRef Adewuya O, Irie Y, Bian K, Onigu-Otite E, Murad F. Mechanism of vasculitis and aneurysms in Kawasaki disease: role of nitric oxide. Nitric Oxide. 2003;8(1):15–25.CrossRef
20.
Zurück zum Zitat Manginas A, Cokkinos DV. Coronary artery ectasias: imaging, functional assessment and clinical implications. Eur Heart J. 2006;27(9):1026–31.CrossRef Manginas A, Cokkinos DV. Coronary artery ectasias: imaging, functional assessment and clinical implications. Eur Heart J. 2006;27(9):1026–31.CrossRef
21.
Zurück zum Zitat Barry RJ, Nguyen QD, Lee RW, Murray PI, Denniston AK. Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol. 2014;8:1891–911.PubMedPubMedCentral Barry RJ, Nguyen QD, Lee RW, Murray PI, Denniston AK. Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol. 2014;8:1891–911.PubMedPubMedCentral
22.
Zurück zum Zitat Wong KW, D’Amico DJ, Hedges TR 3rd, Soong HK, Schooley RT, Kenyon KR. Ocular involvement associated with chronic Epstein–Barr virus disease. Arch Ophthalmol. 1987;105(6):788–92.CrossRef Wong KW, D’Amico DJ, Hedges TR 3rd, Soong HK, Schooley RT, Kenyon KR. Ocular involvement associated with chronic Epstein–Barr virus disease. Arch Ophthalmol. 1987;105(6):788–92.CrossRef
23.
Zurück zum Zitat Morishima N, Miyakawa S, Akazawa Y, Takagi S. A Case of uveitis associated with chronic active Epstein–Barr virus infection. Ophthalmologica. 1996;210(3):186–8.CrossRef Morishima N, Miyakawa S, Akazawa Y, Takagi S. A Case of uveitis associated with chronic active Epstein–Barr virus infection. Ophthalmologica. 1996;210(3):186–8.CrossRef
24.
Zurück zum Zitat Blum-Hareuveni T, Seguin-Greenstein S, Kramer M, Hareuveni G, Sharon Y, Friling R, Sharief L, Lightman S, Tomkins-Netzer O. Risk factors for the development of cataract in children with uveitis. Am J Ophthalmol. 2017;177:139–43.CrossRef Blum-Hareuveni T, Seguin-Greenstein S, Kramer M, Hareuveni G, Sharon Y, Friling R, Sharief L, Lightman S, Tomkins-Netzer O. Risk factors for the development of cataract in children with uveitis. Am J Ophthalmol. 2017;177:139–43.CrossRef
25.
Zurück zum Zitat Nakagawa A, Ito M, Saga S. Fatal cytotoxic T-cell proliferation in chronic active Epstein–Barr virus infection in childhood. Am J Clin Pathol. 2002;117(2):283–90.CrossRef Nakagawa A, Ito M, Saga S. Fatal cytotoxic T-cell proliferation in chronic active Epstein–Barr virus infection in childhood. Am J Clin Pathol. 2002;117(2):283–90.CrossRef
26.
Zurück zum Zitat Kikuta H, Sakiyama Y, Matsumoto S, Hamada I, Yazaki M, Iwaki T, Nakano M. Detection of Epstein–Barr virus DNA in cardiac and aortic tissues from chronic, active Epstein–Barr virus infection associated with Kawasaki disease-like coronary artery aneurysms. J Pediatr. 1993;123(1):90–2.CrossRef Kikuta H, Sakiyama Y, Matsumoto S, Hamada I, Yazaki M, Iwaki T, Nakano M. Detection of Epstein–Barr virus DNA in cardiac and aortic tissues from chronic, active Epstein–Barr virus infection associated with Kawasaki disease-like coronary artery aneurysms. J Pediatr. 1993;123(1):90–2.CrossRef
27.
Zurück zum Zitat Fukuda Y, Momoi N, Akaihata M, Nagasawa K, Mitomo M, Aoyagi Y, Endoh K, Hosoya M. Pulmonary arterial hypertension associated with chronic active Epstein–Barr virus infection. Pediatr Int. 2015;57(4):731–4.CrossRef Fukuda Y, Momoi N, Akaihata M, Nagasawa K, Mitomo M, Aoyagi Y, Endoh K, Hosoya M. Pulmonary arterial hypertension associated with chronic active Epstein–Barr virus infection. Pediatr Int. 2015;57(4):731–4.CrossRef
28.
Zurück zum Zitat Murakami K, Ohsawa M, Hu SX, Kanno H, Aozasa K, Nose M. Large-vessel arteritis associated with chronic active Epstein–Barr virus infection. Arthritis Rheum. 1998;41(2):369–73.CrossRef Murakami K, Ohsawa M, Hu SX, Kanno H, Aozasa K, Nose M. Large-vessel arteritis associated with chronic active Epstein–Barr virus infection. Arthritis Rheum. 1998;41(2):369–73.CrossRef
29.
Zurück zum Zitat Kikuta H, Taguchi Y, Tomizawa K, Kojima K, Kawamura N, Ishizaka A, Sakiyama Y, Matsumoto S, Imai S, Kinoshita T, et al. Epstein–Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature. 1988;333(6172):455–7.CrossRef Kikuta H, Taguchi Y, Tomizawa K, Kojima K, Kawamura N, Ishizaka A, Sakiyama Y, Matsumoto S, Imai S, Kinoshita T, et al. Epstein–Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature. 1988;333(6172):455–7.CrossRef
30.
Zurück zum Zitat Toubo T, Ohga S, Takada H, Suga N, Nomura A, Ohno T, Hara T. Rheumatic fever-mimicking carditis as a first presentation of chronic active Epstein–Barr virus infection. Acta Paediatr. 2006;95(5):614–8.CrossRef Toubo T, Ohga S, Takada H, Suga N, Nomura A, Ohno T, Hara T. Rheumatic fever-mimicking carditis as a first presentation of chronic active Epstein–Barr virus infection. Acta Paediatr. 2006;95(5):614–8.CrossRef
31.
Zurück zum Zitat Kobayashi I, Hamada I, Tomizawa K, Kikuta H, Sakiyama Y, Matsumoto S. Chronic Epstein–Barr virus infections associated with coronary aneurysms. Acta Paediatr Jpn. 1989;31(4):509–12.CrossRef Kobayashi I, Hamada I, Tomizawa K, Kikuta H, Sakiyama Y, Matsumoto S. Chronic Epstein–Barr virus infections associated with coronary aneurysms. Acta Paediatr Jpn. 1989;31(4):509–12.CrossRef
32.
Zurück zum Zitat Ohga S, Kimura N, Takada H, Nagano M, Ohshima K, Nomura A, Muraoka K, Take H, Yamamori S, Hara T. Restricted diversification of T-cells in chronic active Epstein–Barr virus infection: potential inclination to T-lymphoproliferative disease. Am J Hematol. 1999;61(1):26–33.CrossRef Ohga S, Kimura N, Takada H, Nagano M, Ohshima K, Nomura A, Muraoka K, Take H, Yamamori S, Hara T. Restricted diversification of T-cells in chronic active Epstein–Barr virus infection: potential inclination to T-lymphoproliferative disease. Am J Hematol. 1999;61(1):26–33.CrossRef
33.
Zurück zum Zitat Nishimura S, Ehara S, Hanatani A, Yoshiyama M. Chronic active Epstein–Barr virus infection complicated with multiple artery aneurysms. Eur Heart J Cardiovasc Imaging. 2014;15(11):1255.CrossRef Nishimura S, Ehara S, Hanatani A, Yoshiyama M. Chronic active Epstein–Barr virus infection complicated with multiple artery aneurysms. Eur Heart J Cardiovasc Imaging. 2014;15(11):1255.CrossRef
34.
Zurück zum Zitat Jiang S, Li X, Cao J, Wu D, Kong L, Lin L, Jin Z, An J, Wang Y. Early diagnosis and follow-up of chronic active Epstein–Barr-virus-associated cardiovascular complications with cardiovascular magnetic resonance imaging: A case report. Medicine (Baltimore). 2016;95(31):e4384.CrossRef Jiang S, Li X, Cao J, Wu D, Kong L, Lin L, Jin Z, An J, Wang Y. Early diagnosis and follow-up of chronic active Epstein–Barr-virus-associated cardiovascular complications with cardiovascular magnetic resonance imaging: A case report. Medicine (Baltimore). 2016;95(31):e4384.CrossRef
35.
Zurück zum Zitat Xie XF, Huang P, Zhang L. A case of chronic active Epstein–Barr virus infection with concomitant giant coronary artery aneurysm. Zhonghua Er Ke Za Zhi. 2016;54(10):779–80.PubMed Xie XF, Huang P, Zhang L. A case of chronic active Epstein–Barr virus infection with concomitant giant coronary artery aneurysm. Zhonghua Er Ke Za Zhi. 2016;54(10):779–80.PubMed
36.
Zurück zum Zitat Ba H, Xu L, Peng H, Lin Y, Li X, Wang H, Qin Y. Chronic active Epstein–Barr virus infection with systemic vasculitis and pulmonary arterial hypertension in a child. Front Pediatr. 2019;7:219.CrossRef Ba H, Xu L, Peng H, Lin Y, Li X, Wang H, Qin Y. Chronic active Epstein–Barr virus infection with systemic vasculitis and pulmonary arterial hypertension in a child. Front Pediatr. 2019;7:219.CrossRef
Metadaten
Titel
Chronic active Epstein–Barr virus infection manifesting as coronary artery aneurysm and uveitis
verfasst von
Haijuan Xiao
Bing Hu
Rongmu Luo
Huili Hu
Junmei Zhang
Weiying Kuang
Rui Zhang
Li Li
Gang Liu
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
Virology Journal / Ausgabe 1/2020
Elektronische ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-020-01409-8

Weitere Artikel der Ausgabe 1/2020

Virology Journal 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.